This legislation aims to update and extend the user fee program for over-the-counter (OTC) monograph drugs, allowing the Food and Drug Administration (FDA) to collect fees from manufacturers to fund regulatory activities associated with these products. The primary goal is to ensure the FDA has adequate resources to effectively oversee OTC drugs while establishing clearer guidelines for fee assessments and adjustments.